ClinicalTrials.gg
Active, not recruitingNCT02202590Updated Oct 2, 2026

Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus

An interventional study of SECM Capsule in Eosinophilic Esophagitis, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Oct 2013, registered Jun 2014).
Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 165 studies in Eosinophilic Esophagitis with a site in United States — 23 open to participants now, 40 under way, 3 of them phase 3. Eosinophilic Esophagitis · United States.

Planned enrollment
26th of 111
96 · median 36
Started
2013
with 8 others
No phase
33 of 165
4 open now
Primary completion
2028-12
later than 32 of 39 live
Registered
55th of 165
by date

Among the 165 studies in Eosinophilic Esophagitis with a site in United States, this one is the 26th largest by planned enrollment of the 111 interventional ones that give a count, is one of 9 that started in 2013, is one of 33 with no phase, reaches primary completion later than 32 of the 39 other live ones, and was the 55th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

23 of the 165 studies in Eosinophilic Esophagitis with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Eosinophilic Esophagitis studies recruiting now, 13 (30%) set no upper age limit and 27 (63%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 14 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Eosinophilic Esophagitis with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to test the feasibility and the tolerability of a tethered spectrally encoded confocal microscopy (SECM) capsule and to use it to image the esophagus.

Read the detailed description

96 participants including healthy volunteers, patients with a suspicion of having Eosinophilic Esophagitis (EoE) and patients with a current or prior clinical diagnosis of EoE will be recruited and asked to swallow the SECM capsule while being awake and unsedated. The capsule is attached to a tether which allows the operator to control as well as navigate the capsule as it progresses down the esophagus using natural propulsive force called peristalsis.

As the capsule progresses, multiple 2-dimensional cross-sectional images of the esophagus are acquired. Images are analyzed at a later stage.

03

Conditions studied

  • Eosinophilic Esophagitis

Keywords

  • SECM
  • Esophagus
  • Eosinophilic Esophagitis
  • Allergy
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be a healthy volunteer
  • OR participant must have a suspicion of EoE
  • OR participant must have a prior clinical suspicion of EoE
  • Participant must be older than 14 years of age
  • Participant must be able to give

Exclusion criteria

Exclusion Criteria:

  • Participants with the inability to swallow pills and capsules.
  • Esophageal fistula and/or esophageal strictures with a stricture diameter that is smaller than the diameter of the capsule.
  • Participants with prior endoscopic ablation or resection treatment of Barrett's Esophagus (BE)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Imaging

    Participant will swallow the SECM capsule and Imaging will be performed using the SECM Imaging system.

    Device: SECM Capsule

Interventions

  • DeviceSECM Capsule

    Imaging of the esophagus using the SECM capsule and system

06

What researchers measure

Primary outcomes

  1. SECM Imaging quality. Assessed qualitative values like resolution, tissue architecture, background scatter etc.

    An investigator will qualitatively assess the the Feasibility of SECM Capsule and Imaging in EoE participant versus Healthy Controls. He will assess the quality of the recorded images and movies obtained with each exam after the imaging is completed. The images obtained by the SECM Capsule will be compared to the images obtained by clinical endoscopy if available.

    Time frame: A single 20 minute visit (5-7 minute imaging).

  2. Tolerability of SECM Capsule Imaging Procedure in Healthy and EoE Participant, measured by feedback scores.

    After participating in the study, the participants will be asked for feedback about tolerability of the procedure using a questionnaire. This entails questions about discomfort levels and the participants ability to tolerate the tether and capsule during the whole and parts of the procedures. using a 0 -10 scale, participants will score how comfortable the procedure was during each stage. 10 being the most discomfort and 0 being the least discomfort.

    Time frame: Questionnaire adminstered directly after the imaging portion has been completed.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2013 (actual). Primary completion is estimated for Dec 2028, 182 months after the start.

Of 24 interventional studies with no phase under Eosinophilic Esophagitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 41. This study's planned 182 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2026 → Dec 2028 and completion Dec 2028 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2014
First posted
Jul 29, 2014
StartActual
Oct 2013
Primary completionEst.
Dec 2028was Dec 2026
CompletionEst.
Dec 2030was Dec 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Dec 2028
Oct 2, 2026
Study completion
Dec 2028→Dec 2030
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Dec 2026→Dec 2028
    Study completion Dec 2028→Dec 2030
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02202590
Responsible party
Guillermo Tearney (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Jul 29, 2014
Start date
Oct 2013
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 2, 2026

Study contacts

Guillermo Tearney, MD., PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion